Wikipedia:WikiProject Chemicals/Chembox validation/VerifiedDataSandbox and Azatadine: Difference between pages

{{short description|Chemical compound}}

{{cs1 config|name-list-style=vanc}}

{{distinguish|azetidine}}

| verifiedrevid = 477164914

| IUPAC_name = 11-(1-Methylpiperidin-4-ylidene)-6,11-dihydro-5''H''-benzo[5,6]cyclohepta[1,2-''b'']pyridine

| pregnancy_US = B

| legal_US =

| IUPHAR_ligand = 7119

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| C=20 | H=22 | N=2

'''Azatadine''' ('''Optimine''') is a [[first-generation antihistamine]] and [[anticholinergic]] drug that was synthesized in 1963 by [[Schering-Plough]], a former American pharmaceutical company.<ref>{{cite journal | vauthors = Katelaris C | title = Comparative effects of loratadine and azatadine in the treatment of seasonal allergic rhinitis | journal = Asian Pacific Journal of Allergy and Immunology | volume = 8 | issue = 2 | pages = 103–7 | date = December 1990 | pmid = 1982614 }}</ref><ref>{{cite journal | vauthors = Small P, Barrett D, Biskin N | title = Effects of azatadine, terfenadine, and astemizole on allergen-induced nasal provocation | journal = Annals of Allergy | volume = 64 | issue = 2 Pt 1 | pages = 129–31 | date = February 1990 | pmid = 1968324 }}</ref>

It was patented in 1967.<ref>{{cite patent | title = Azatadine | inventor = Villani FJ, Caldwell W | country = US | number = 3326924 | gdate = 1967 }}</ref> It has been succeeded by both [[loratadine]] and [[desloratadine]].<ref>{{cite book | vauthors = Horak F | chapter = Antialergic and Vasoactive Drugs for Allergic Rhinitis. Chapter 4 | title = Allergy Frontiers:Therapy and Prevention. | volume = 5 | veditors = Pawankar R, Holgate ST, Rosenwasser LJ | publisher = Springer Science & Business Media | date = 2010 | isbn = 9784431993629 }}</ref>{{rp|53}} and marketing approvals have been widely withdrawn.<ref>{{cite web | work = Drugs.com | url = https://www.drugs.com/mtm/azatadine.html | title = Azatadine }}</ref><ref>{{cite web | work = Federal Register 70 FR 10651 | date = 2005 | url = https://www.federalregister.gov/articles/2005/03/04/05-4158/hospira-inc-et-al-withdrawal-of-approval-of-76-new-drug-applications-and-60-abbreviated-new-drug | author = Food and Drug Administration | title = Docket No.2005N-0058: Hospira, Inc. et al.; Withdrawal of Approval of 76 New Drug Applications and 60 Abbreviated New Drug Applications }} </ref><ref>{{cite web | work = Federal Register 72 FR 8184 | date = 2007 | url = http://www.gpo.gov/fdsys/pkg/FR-2007-02-23/html/E7-3043.htm | author = Food and Drug Administration | title = Docket No. 2004P-0262: Withdrawal of Approval of 128 Suitability Petitions }}</ref><ref>{{cite web | work = Department of Economic and Social Affairs of the United Nations Secretariat | url = https://www.un.org/esa/coordination/CL12.pdf | title = Consolidated List of Products Whose Consumption and/or Sale Have Been Banned, Withdrawn, Severely Restricted or not Approved by Governments Twelfth Issue: Pharmaceuticals | publisher = United Nations | location = New York | date = 2005 }}</ref>{{rp|290}}<ref>{{cite web | work = FDA | url = https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ucm283497.htm | title = OGD Suitability Tracking Report (Sorted by Drug Name) }}</ref>

== See also ==

* [[Azatadine/pseudoephedrine]]

== References ==

{{Reflist}}

{{Antihistamines}}

{{Cholinergics}}

{{Histaminergics}}

{{Tricyclics}}

[[Category:Piperidines]]

[[Category:Benzocycloheptapyridines]]

[[Category:H1 receptor antagonists]]

[[Category:Withdrawn drugs]]

{{respiratory-system-drug-stub}}